XNAS · Medical Instruments & Supplies
Last stored close · Nov 9, 2026
Close · Nov 9, 2026
$178.85+3.92%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
32/100
Weak
Score components
TickerWhale View
ICU Medical scores 32 out of 100 overall, which we rate weak. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%2Weak
- Revenue growth -9.0%
- EPS growth n/a
Valuation
25%12Weak
- P/E 148.9
- EV/Sales 2.5
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#131 / 139sector rank by TickerWhale Score
TickerWhale Score 32 vs sector average 54.6 (-22.6)
Revenue growth (industry)Top 100%
Gross margin (industry)Top 73%
Return on equity (industry)Top 80%
P/E (industry)Pricier than 83%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
80/100Strong vs universe
Ranks 80th of 100 covered names on our technical composite — the composite itself scores 74/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale rates ICUI's technical setup strong — 80th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+20.0%
- vs 50-day+9.7%
Momentum
Mixed
- RSI (14)64 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength15· weak trend
- MACD (12,26,9)buy(histogram 1.268)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-09 · revised_latestValuation multiples
- P/E (TTM)148.9
- P/S (TTM)2.1
- P/B2.1
- EV/EBITDA—
- EV/Sales2.5
- PEG—
Profitability & returns
- Gross margin39.1%
- Net margin1.4%
- ROE1.4%
- Debt/Equity0.57
Growth
- Revenue growth (YoY)-9.0%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $4.5B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: DAL →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ICUICurrentICU Medical | 32 | 74 | 148.9 | — | 2.1 | 2.5 | $178.85 | +3.92% | -9.0% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 82 | 102.1 | — | 12.6 | 9.7 | $98.76 | +5.22% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.8 | — | 5.2 | 1.6 | $289.00 | +2.00% | +7.5% | ||
| EXELExelixis | 77 | 89 | 21.6 | — | 10.1 | 7.5 | $71.74 | +3.12% | +9.2% | ||
| TGTXTG Therapeutics | 77 | 85 | 22.6 | — | 16.5 | 12.8 | $63.38 | +5.94% | +76.1% | ||
| OSCROscar Health Inc - | 74 | 66 | 19.5 | — | 5.2 | 0.5 | $32.14 | +4.86% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.